Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures: 2017-2025

Historic Gains from Sales and Divestitures for Rocket Pharmaceuticals (RCKT) over the last 5 years, with Sep 2025 value amounting to $825,320.

  • Rocket Pharmaceuticals' Gains from Sales and Divestitures rose 40.31% to $825,320 in Q3 2025 from the same period last year, while for Sep 2025 it was $825,320, marking a year-over-year increase of 40.31%. This contributed to the annual value of $722,471 for FY2024, which is 77.02% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $825,320 for Q3 2025, which was up 72.56% from $478,289 recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $825,320 for Q3 2025, and its period low was $10,168 during Q1 2022.
  • For the 3-year period, Rocket Pharmaceuticals' Gains from Sales and Divestitures averaged around $424,547, with its median value being $408,119 (2023).
  • Data for Rocket Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY soared of 2,872.77% (in 2023) over the last 5 years.
  • Over the past 4 years, Rocket Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $38,966 in 2022, then surged by 947.37% to $408,119 in 2023, then soared by 77.02% to $722,471 in 2024, then soared by 40.31% to $825,320 in 2025.
  • Its Gains from Sales and Divestitures was $825,320 in Q3 2025, compared to $478,289 in Q2 2025 and $300,068 in Q1 2025.